Navigation Links
Obesity may affect response to breast cancer treatment
Date:7/16/2012

Women who are obese continue to have higher levels of oestrogen than women of normal weight even after treatment with hormone-suppressing drugs, raising the possibility that they might benefit from changes to their treatment.

The study, led by a team at The Institute of Cancer Research in London and The Royal Marsden NHS Foundation Trust, found hormone-suppressing drugs did markedly reduce oestrogen levels in obese women but that their levels of oestrogen remained more than double those of women of normal weight.

The research, which is published today in the Journal of Clinical Oncology, could lead to improvements in doctors' ability to select the most appropriate treatment for overweight and obese women. But scientists stressed the effect of obesity was modest and that women taking breast cancer treatment should not be concerned by the findings.

Over three-quarters of breast cancers require oestrogen to grow, so one of the main ways of treating the disease is by blocking the hormone's production or action. Obese women have higher levels of oestrogen than women of normal weight, and the new findings show that although their oestrogen levels are markedly reduced with hormone-suppressing drugs called aromatase inhibitors, the levels are higher during treatment than those in similarly treated normal weight women.

Senior author Professor Mitch Dowsett, a team leader in the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research and head of the academic department of biochemistry at The Royal Marsden, said: "We found that women with higher BMIs had more oestrogen remaining in their blood after treatment than healthy-weight women, which is consistent with previous suggestions that aromatase inhibitors might be slightly less effective in these women.

"Our findings are based on laboratory studies, so we would need to carry out clinical trials to tell us whether women with a higher BMI would benefit from changes to their treatment. Women with higher BMIs should certainly not be alarmed by this finding or stop taking their treatment. Our study takes us a step closer to understanding which of the treatment options available might be the most suitable for individual women."

Professor Dowsett and colleagues set out to probe a recent study that indicated the aromatase inhibitor anastrozole was no more effective than older-style tamoxifen in women with higher BMI, unlike in the general population where it is clearly more effective.

One possible explanation is that tamoxifen is more effective in overweight women, but the team wanted to investigate the other possibility that in these women aromatase inhibitors are less effective.

The scientists examined two aromatase inhibitors: anastrozole and a more potent drug called letrozole. The study included 54 postmenopausal women with oestrogen receptor positive breast cancer who were treated at the Edinburgh Breast Unit with either three months of adjuvant anastrozole followed by three months of letrozole, or the drugs in the opposite sequence. Data on body mass index (BMI) and oestrogen levels before and after treatment with the first drug, as measured by levels of estradiol and oestrone sulphate in the blood - were available for 44 patients.

The study found that, prior to treatment, women with higher BMIs had higher oestrogen levels those with BMIs from 30 to 35 had around three times more plasma oestrogen than those with BMIs of less than 25.

After treatment with letrozole, women with BMIs of 30 to 35 still had levels of plasma oestrogen nearly three times as high as for healthy-weight women. The same trend was found for anastrozole, but did not reach statistical significance.

Professor Alan Ashworth, Chief Executive of The Institute of Cancer Research, said: "Aromatase inhibitors have played an increasing role in breast cancer treatment over the past decade, so it is important to understand the factors that affect how well they work in individual women in order to allow doctors to choose the best possible drug from the range available."


'/>"/>

Contact: Tatjana Trposka
tatjana.trposka@icr.ac.uk
44-207-153-5312
Institute of Cancer Research
Source:Eurekalert

Related medicine news :

1. Obesity Might Hinder Treatment of Some Breast Cancers
2. Obesity Alone May Not Hurt Kids Classroom Performance
3. New evidence for link between obesity and circle of friends
4. Vanderbilt study finds obesity linked to kidney injury after heart surgery
5. Obesity, larger waist size associated with better outcomes in heart failure patients
6. Why current strategies for fighting obesity are not working
7. Wayne State University researcher seeks to understand link between obesity, flu severity
8. Researchers find abuse during childhood may contribute to obesity in adulthood
9. Racial make-up of community impacts obesity risk
10. Screen All Adults for Obesity: U.S. Panel
11. STOP Obesity Alliance new state-level members share obstacles, opportunities in addressing obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology: